In China, bisphosphonates are the most commonly prescribed drug class for the treatment of osteoporosis. Hospital use of osteoporosis drugs in China is driving the demand in five cities: Shanghai, Beijing, Guangzhou, Hangzhou, and Chongqing.
Statistics:
The global and China osteoporosis drugs market is expected to account around US$ 17.1 Bn in terms of value by the end of 2027.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/4018
Market Drivers:
Rising number in approvals and launches of novel drugs is expected to drive growth of the global and China osteoporosis drugs market during the forecast period. For instance, in June 2020, BeiGene Co., Ltd. begun commercializing XGEVA (denosumab) in China for the treatment of giant cell tumor of bone.
Market Opportunities:
New therapeutics are being developed through clinical trials, which is expected to pose attractive growth opportunities for major players in the global and China osteoporosis drugs market. For instance, in July 2020, Entera Bio Ltd. reported that the Phase 2 protocol has been developed to include the testing of higher doses of EB613 in postmenopausal women with osteoporosis, following approval by the Institutional Review Boards at the clinical sites.
Market Restraints:
The global and China osteoporosis drugs market’s development is expected to be hamper due to the adverse effects of osteoporosis medications. For instance, Back pain, headaches, redness or swelling of the eyes, diarrhea, flu-like symptoms, nausea or stomach upset, pain in the arms or legs, or redness or swelling where Boniva was administered, are all possible side effects of ibandronate.
Key Takeaways:
The global and China osteoporosis drugs market was accounted around US$ 12.7 Bn in 2019 and is forecast to reach a value over US$ 17.1 Bn by 2027 at a CAGR over 3.8% between 2020 and 2027. Rising approval and launch of novel drugs by major companies, is expected to drive growth of the global and China osteoporosis drugs market during the forecast period.
Hospitals segment held dominant position in the global and China osteoporosis drugs market in 2019, accounting around 45.4% share in terms of value, the segment’s growth is due to an rising incidences of osteoporosis in both developed and emerging economies over the forecast period.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/4018
Market Trends
The acceptance and introduction of biosimilars of generic osteoporosis drugs is a priority for the market’s major players. For instance, in May 2020, JHL Biotech Inc. randomized and dosed the first group of subjects in the company’s Australian Phase I Clinical Trial of JHL1266, in healthy volunteers, a possible biosimilar to denosumab was tested for pharmacokinetics, pharmacodynamics, and immunogenicity.
Drug recalls are a common occurrence in the global and China osteoporosis drugs market. For instance, in March 2020, Taro Pharmaceuticals Inc. recalled five lots of Taro-Zoledronic acid injection 5mg/100ml, which is used for osteoporosis and Paget’s disorder treatment, due to the potential presence of particulate matter in the drug.
Competitive Landscape
Key players are dominating in the global and China osteoporosis drugs market such as, Eli Lilly, Merck & Co., Enzo Biochem, Inc., Procter & Gamble, Novartis, Sanofi-Aventis, Wyeth, GlaxoSmithKline, Roche, Amgen, UCB, Bone Biologics, BeiGene Co., Ltd., JHL Biotech Inc., Keros Therapeutics, Taro Pharmaceuticals Inc., and Teijin Pharma Limited.
Key Developments
May 2020: Enzo Biochem, Inc. was issued a U.S. patent for methods for developing monoclonal antibodies against particular regions of human Sclerostin, a protein that is a negative regulator of bone growth and an osteoporosis drug target
January 2020: Bone Biologics, a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model
Reasons to Purchase this Report
• Current and future of Global and China Osteoporosis Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product launch
- PEST Analysis
- Technological Advancements
- Regulatory Scenario
- Mergers and Acquisitions
- Impact of COVID19 on market
- Market Dynamics
- Global and China Osteoporosis Drugs Market, By Drug Type, 2019 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Bisphosphonates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Alendronate
- Risedronate
- Ibandronate
- Zoledronic Acid
- Others
- Calcitonin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Selective Estrogen Receptor Modulators (SERMs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Rank Ligand (RANKL) Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global and China Osteoporosis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global and China Osteoporosis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
- Introduction
- Global and China Osteoporosis Drugs Market, By Region, 2019 – 2027, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- Germany
- U.K.
- France
- Spain
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- Japan
- India
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- China
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Merck & Co.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eli Lilly
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Procter & Gamble
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Enzo Biochem, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi-Aventis
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Wyeth
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Roche
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- UCB
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Amgen
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BeiGene Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bone Biologics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teijin Pharma Limited
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JHL Biotech Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Keros Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Taro Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co.
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837